- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.05. | Praxis Precision Medicines, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 12.05. | Wedbush Maintained an Underperform Rating on Praxis Precision Medicines, Inc. (PRAX) | 5 | Insider Monkey | ||
| 07.05. | Jefferies raises Praxis Precision Medicines stock price target on pipeline catalysts | 3 | Investing.com | ||
| 07.05. | Praxis Precision übertrifft EPS-Prognosen für Q1 2026 | 3 | Investing.com Deutsch | ||
| 07.05. | Praxis Precision Medicines GAAP EPS of -$3.20 | 1 | Seeking Alpha | ||
| PRAXIS PRECISION MEDICINES Aktie jetzt für 0€ handeln | |||||
| 07.05. | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.05. | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | 614 | GlobeNewswire (Europe) | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| 29.04. | Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide | 3 | Insider Monkey | ||
| 27.04. | Praxis Precision Medicines Inc. (PRAX): Rare Triple-Catalyst Setup in Neurology | 6 | Insider Monkey | ||
| 23.04. | Praxis Precision Medicines (PRAX): One of the Best Upside Stocks | 4 | Insider Monkey | ||
| 14.04. | Praxis Precision Medicines: FDA akzeptiert Zulassungsantrag für Tremor-Medikament - Aktie im Aufwind | 2 | Investing.com Deutsch | ||
| 14.04. | Jones Trading bestätigt Kaufempfehlung für Praxis Precision Medicines nach Annahme von FDA-Zulassungsantrag | 7 | Investing.com Deutsch | ||
| 14.04. | Jones Trading reiterates Praxis Precision Medicines stock Buy rating on FDA filing acceptance | 1 | Investing.com | ||
| 14.04. | Praxis Precision Medicines, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.04. | Why Is Praxis Precision Stock Soaring Tuesday? | 1 | Benzinga.com | ||
| 14.04. | Praxis Precision Medicines stock rating reiterated at Buy by BTIG | 1 | Investing.com | ||
| 14.04. | Praxis Precision Medicines: BTIG bekräftigt "Buy"-Rating und Kursziel von 843 US-Dollar | 1 | Investing.com Deutsch | ||
| 14.04. | Jefferies reiterates Praxis Precision Medicines stock rating on FDA review | 1 | Investing.com | ||
| 14.04. | Praxis Precision Says FDA Accepts Ulixacaltamide HCl NDA For Review To Treat Essential Tremor | 2 | RTTNews | ||
| 14.04. | Praxis Precision gains as lead asset accepted for FDA review | 1 | Seeking Alpha |
1 2 3 4 5 Weiter >>
118 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,816 | +1,60 % | Evotec zapft den Kapitalmarkt an | Evotec platziert Wandelanleihen über 116,1 Mio. EUR und finanziert damit das Transformationsprogramm "Project Horizon". Die Evotec SE hat sich frisches Kapital über den Wandelanleihemarkt gesichert.... ► Artikel lesen | |
| QIAGEN | 29,665 | -0,17 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| MODERNA | 39,675 | +0,72 % | Hedge Fund and Insider Trading News: Bill Ackman, Ray Dalio, Warren Buffett, Viking Global, Darsana Capital Partners, Caxton Associates, Balyasny Asset Management, D1 Capital Partners, Republic Services Inc (RSG), Moderna Inc (MRNA), and More | ||
| AMGEN | 286,30 | +0,46 % | Dividendenbekanntmachungen (15.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A10 NETWORKS INC US0021211018 0,06 USD 0,0514 EUR AF GRUPPEN ASA NO0003078107 6,5 NOK 0,6029 EUR AGCO CORPORATION US0010841023 0... ► Artikel lesen | |
| NOVAVAX | 7,630 | -0,65 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| BIOGEN | 165,10 | +0,55 % | Biogen Inc.: Biogen Completes Acquisition of Apellis Pharmaceuticals |
CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis... ► Artikel lesen | |
| ILLUMINA | 122,20 | +0,13 % | RBC Capital assumes Illumina stock coverage with outperform rating | ||
| CRISPR THERAPEUTICS | 41,245 | +0,57 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. "The first quarter reflected... ► Artikel lesen | |
| OCUGEN | 1,122 | -0,36 % | Ocugen schließt Platzierung von Wandelanleihen über 130 Millionen US-Dollar ab | ||
| INOVIO PHARMACEUTICALS | 1,061 | +0,47 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,560 | +2,72 % | Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry? | ||
| COSCIENS BIOPHARMA | 1,260 | 0,00 % | COSCIENS Biopharma Inc. Reports Q1 2026 Results | TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company") today reported its financial and operating results for the first... ► Artikel lesen | |
| EDITAS MEDICINE | 2,100 | -1,41 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,562 | +0,03 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 43,440 | +1,21 % | BioMarin Pharmaceutical Inc.: BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency | ENERGY 3 study met 1 of 2 co-primary endpoints in children with ENPP1 deficiency
Treatment with BMN 401 led to statistically significant increases in plasma inorganic... ► Artikel lesen |
PRAXIS PRECISION MEDICINES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,44 (+0,14 %) liegt der Kurs bei 321,05 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PRAXIS PRECISION MEDICINES INC finden Sie auf Wallstreet Online.